Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Palbociclib

FDA-approved product (capsule, oral), marketed as Ibrance, Palbociclib.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Palbociclib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • HER2 Positive Breast Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Cyclin-dependent kinase (cdk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Palbociclib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Palbociclib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

    NCT03644186 · start 2019-04-16

    Registered record
    Registry ID
    NCT03644186
    Conditions
    Breast Cancer; Estrogen Receptor Positive Tumor; HER2-positive Breast Cancer
    Interventions
    Paclitaxel; Trastuzumab; Pertuzumab; Palbociclib; Letrozole; Trastuzumab; Pertuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-04-16
    Completion
    2023-04-14
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Estrogen Receptor Positive Tumor; HER2-positive Breast Cancer
    InterventionPaclitaxel; Trastuzumab; Pertuzumab; Palbociclib +3 more
    PhasePhase 2
    Registry statusCompleted

  • RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

    NCT04460898 · start 2019-01-04

    Registered record
    Registry ID
    NCT04460898
    Conditions
    Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-01-04
    Completion
    2019-06-24
    Enrolment
    195

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

    NCT03526250 · start 2018-08-13

    Registered record
    Registry ID
    NCT03526250
    Conditions
    Advanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma
    Interventions
    Laboratory Biomarker Analysis; Palbociclib; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-08-13
    Completion
    2024-09-30
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma +28 more
    InterventionLaboratory Biomarker Analysis; Palbociclib; Pharmacological Study
    PhasePhase 2
    Registry statusCompleted

  • Analysis of Circulating Tumor Markers in Blood

    NCT04025541 · start 2018-05-29

    Registered record
    Registry ID
    NCT04025541
    Conditions
    Cancer; Breast Cancer; Sarcoma; Lung Cancers; Glioma; Colon Cancer
    Interventions
    Blood sampling; Blood sampling C3; Blood sampling C4/7/10/13; Blood sampling C5; Blood sampling C6; Blood sampling C8; Blood sampling C9; Blood sampling C11 + FFPE; Blood sampling C12
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2018-05-29
    Completion
    2029-05-29
    Enrolment
    992

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Breast Cancer; Sarcoma; Lung Cancers +2 more
    InterventionBlood sampling; Blood sampling C3; Blood sampling C4/7/10/13; Blood sampling C5 +5 more
    PhaseNot applicable
    Registry statusRecruiting

  • Treatment After Palbociclib-containing Regimens

    NCT04517318 · start 2017-08-15

    Registered record
    Registry ID
    NCT04517318
    Conditions
    Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-08-15
    Completion
    2021-07-15
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

    NCT03227328 · start 2017-08-02

    Registered record
    Registry ID
    NCT03227328
    Conditions
    Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer
    Interventions
    concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy; chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-08-02
    Completion
    2022-07-01
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer
    Interventionconcomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy; chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
    PhasePhase 2
    Registry statusCompleted

  • Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

    NCT03220178 · start 2017-07-24

    Registered record
    Registry ID
    NCT03220178
    Conditions
    Breast Neoplasm
    Interventions
    Palbociclib; Fulvestrant; Anastrozole; Letrozole; Exemestane
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-07-24
    Completion
    2021-12-07
    Enrolment
    532

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasm
    InterventionPalbociclib; Fulvestrant; Anastrozole; Letrozole +1 more
    PhasePhase 4
    Registry statusTerminated

  • Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

    NCT04524728 · start 2016-12

    Registered record
    Registry ID
    NCT04524728
    Conditions
    Breast; Neoplasm Malignant; Female
    Interventions
    Palbociclib; Letrozole 2.5mg; Fulvestrant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-12
    Completion
    2020-06
    Enrolment
    191

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast; Neoplasm Malignant; Female
    InterventionPalbociclib; Letrozole 2.5mg; Fulvestrant
    PhaseNot recorded
    Registry statusCompleted

  • Palbociclib and FES PET

    NCT02806050 · start 2016-09-16

    Registered record
    Registry ID
    NCT02806050
    Conditions
    Breast Cancer
    Interventions
    Palbociclib; FES PET; Letrozole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-09-16
    Completion
    2022-09-28
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionPalbociclib; FES PET; Letrozole
    PhasePhase 2
    Registry statusCompleted

  • Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

    NCT02774681 · start 2016-08-31

    Registered record
    Registry ID
    NCT02774681
    Conditions
    Breast Carcinoma Metastatic in the Brain; Estrogen Receptor Negative; HER2/Neu Negative; HER2/Neu Positive; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer
    Interventions
    Cognitive Assessment; Palbociclib; Quality-of-Life Assessment; Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-08-31
    Completion
    2020-02-16
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Carcinoma Metastatic in the Brain; Estrogen Receptor Negative; HER2/Neu Negative; HER2/Neu Positive +3 more
    InterventionCognitive Assessment; Palbociclib; Quality-of-Life Assessment; Trastuzumab
    PhasePhase 2
    Registry statusTerminated

  • Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

    NCT02630693 · start 2016-04-08

    Registered record
    Registry ID
    NCT02630693
    Conditions
    Breast Cancer
    Interventions
    Palbociclib 100mg; Palbociclib 125mg; Fulvestrant or Tamoxifen or Aromatase Inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-04-08
    Completion
    2023-11-29
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionPalbociclib 100mg; Palbociclib 125mg; Fulvestrant or Tamoxifen or Aromatase Inhibitor
    PhasePhase 2
    Registry statusCompleted

  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    NCT02465060 · start 2015-08-17

    Registered record
    Registry ID
    NCT02465060
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
    Interventions
    Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-17
    Completion
    2026-12-31
    Enrolment
    6,452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 more
    InterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

    NCT02491983 · start 2015-08

    Registered record
    Registry ID
    NCT02491983
    Conditions
    Metastatic Breast Cancer
    Interventions
    Palbociclib; Fulvestrant; Letrozole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-08
    Completion
    2020-01
    Enrolment
    486

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionPalbociclib; Fulvestrant; Letrozole
    PhasePhase 2
    Registry statusCompleted

  • A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

    NCT02296801 · start 2015-01

    Registered record
    Registry ID
    NCT02296801
    Conditions
    Breast Cancer; Breast Carcinoma; Breast Tumors
    Interventions
    Letrozole; palbociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01
    Completion
    2019-03
    Enrolment
    307

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Breast Carcinoma; Breast Tumors
    InterventionLetrozole; palbociclib
    PhasePhase 2
    Registry statusCompleted

  • Randomized Phase II Study to Assess PD 0332991 in Breast Cancer

    NCT02008734 · start 2014-01

    Registered record
    Registry ID
    NCT02008734
    Conditions
    Untreated Operable Early Breast Cancer
    Interventions
    PD0332991
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-01
    Completion
    2016-01
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUntreated Operable Early Breast Cancer
    InterventionPD0332991
    PhasePhase 2
    Registry statusCompleted